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ABSTRACT 
Eosinophilic endomyocarditis is a manifestation of hypereosinophilic syndrome, characterized by prolonged (>6 
months), unexplained peripheral blood eosinophilia (>1,500 cells/mm
3) with end-organ damage in unknown causes. 
We report a case of a 42-year-old patient who developed eosinophilic endomyocarditis following upper respiratory 
tract symptoms for 2 months. Additionally, endomyocarditis was combined with massive pleural effusion and peri-
cardial effusion, which have not been reported in Korea. (Korean Circ J 2009;39:545-547) 
 





Associations among progressive cardiac failure, eosin-
ophilia, and multi-organ dysfunction were first described 
by Loeffler in 1936. It was then described as hypereosin-
ophilic syndrome, and diagnostic criteria were proposed 
as prolonged (>6 months) and unexplained peripheral 
blood eosinophilia (>1,500 cells/mm
3) with end-organ 
(heart, lung, gastrointestinal tract, brain, skin, bone mar-
row) damage in unknown causes.
1) In such a pheno-
menon, cardiac manifestation (40-50% of patients) is 
frequent and damage to the endomyocardium is caused 
by deposition of toxic granule proteins.
2) In Korea, a 
case of Loeffler’s endocarditis with acute obstruction of 
the common iliac artery was reported in 1999.
3)  
We report a case of a 42-year-old patient in whom 
eosinophilic endomyocarditis developed following upper 
respiratory tract symptoms for 2 months. Additionally, 
endomyocarditis was combined with massive pleural 
effusion and pericardial effusion, which have been not 
reported in Korea.   
Case  
 
A 42-year-old female patient was admitted to our out-
patient clinic with symptoms of pleural chest pain, cough, 
and dyspnea on exertion. Her medication history includ-
ed anti-histamine for two months due to upper respira-
tory symptoms at a primary clinic. Blood pressure was 
120/80 mmHg, heart rate was 100 bpm, respiratory rate 
was 20 per minute, and body temperature was normal. 
On physical examination, the sound of decreased breath-
ing was observed in the right lower lung. Cardiac auscul-
tation was otherwise normal. Initial laboratory findings 
revealed hypereosinophilia (660 cells/mm
3), with nega-
tive parasitological tests and a negative result for Anti-
neutrophil cytoplasmic antibodies (ANCA), with mildly 
elevated CK-MB (5.23 ng/mL). EKG showed a slightly 
elevated ST segment in precordial leads (V1, 2, 3, 4). 
Chest X-ray revealed a right-sided pleural effusion and 
cardiomegaly (Fig. 1A). Transthoracic echocardiography 
showed left ventricular hypertrophy and moderate peri-
cardial effusion without thrombus (Fig. 1C). Left ven-
tricular systolic function was in the low to normal range 
(ejection fraction=51%). Absolute eosinophil count 
then became elevated to 2,269 cells/mm
3; therefore, an 
endomyocardial biopsy was performed. Biopsy specimens 
revealed the deposition of degranulated eosinophils in 
endomyocardium (Fig. 2). A diagnosis of eosinophilic 
endomyocarditis was thus confirmed, and corticoste-
roid therapy (prednisolone, 30 mg/day) was planned. 
One day after the start of medication, absolute eosino-
phil count was reduced from 2,269 cells/mm
3 to 108 
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cells/mm
3, an indication of a good prognosis. Further-
more, follow up transthoracic echocardiography showed 
that pericardial effusion was reduced, and follow up 
chest X-ray showed decreased pleural effusion (Fig. 1B). 
The patient stopped taking prednisolone (2.5 mg/day) 
after 5 months because absolute eosinophil counts were 
within normal limits, and follow up echocardiography 
showed no left ventricular hypertrophy and no residual 
pericardial effusion. Also the ejection fraction improved 
from 51% to 77%. At 9-month follow up, the patient 





Eosinophilic endomyocarditis is a subcategory of hy-
pereosinophilic syndrome. Eosinophilic endomyocardi-
tis is caused by direct infiltration of eosinophils into 
cardiac tissues, so that degranulated eosinophils release 
cardiotoxic substances, including toxic cationic proteins.
4) 
Acute necrosis, thrombosis, and fibrosis subsequently 
occurs by these mechanisms.
4)  
Cardiac evaluation for patients admitted for meeting 
criteria for eosinophilic endocarditis, should include 
baseline EKG, echocardiography, and chest X-ray.
2) Com-
mon findings on the EKG are nonspecific and include 
ST segment abnormalities.
5) Echocardiography often 
shows ventricular hypertrophy, valvular abnormalities, 
mural or apical thrombus, and left ventricle (LV) dia-
stolic dysfunction.
5) However, despite these noninvasive 
and newly developed methods, such as cardiac MRI, 
endomyocardial biopsy is still the gold standard diag-
nostic method, because other cardiac diseases can be 
combined with peripheral eosinophilia.
2) For example, 
Churg-strauss syndrome involving the cardiovascular 
system is almost identical with eosinophilic endomyo-
carditis in its clinical presentation. Furthermore, once 
eosinophilic endomyocarditis is confirmed by biopsy, 
corticosteroids and cytotoxic drugs, such as hydroxyurea 
could be used effectively. Normalization of absolute eos-
inophil counts is the first therapeutic goal. Nearly 70% 
of patients showed a rapid reduction in eosinophils after 
corticosteroid therapy (which are the drugs of first choice) 
was administered.
1)6) 
Typically, endocardium and the underlying myocardi-
um are involved in eosinophilic endomyocarditis.
7) How-
ever, our patient had concurrent pericardial effusion. 
Although no pericardial biopsy was performed, pericar-
dial effusion was suggestive of acute pericarditis. In a re-
view of the English literature, there were 55 patients with 
hypereosinophilic syndrome, with 4% having pericardi-
tis.
7) Pericarditis in eosinophilic endomyocarditis is not 
common, but clinicians should always consider the pos-
sibility of pericarditis in eosinophilic endomyocarditis. 
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C: transthoracic echocardiography (parasternal long axia view) showed left ventricular hypertrophy and moderate pericardial effusion
without thrombus. 
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